General Information of Drug (ID: DMR3J6S)

Drug Name
Cholesterol Drug Info
Synonyms
cholesterol; 57-88-5; Cholesterin; Cholest-5-en-3beta-ol; Cholesteryl alcohol; Cholestrin; Dusoran; Cordulan; Dusoline; Cholesterine; Hydrocerin; Cholestrol; Kathro; Dythol; Lanol; Super hartolan; Provitamin D; Cholesterol base H; Lidinite; Nimco cholesterol base H; Lidinit; Wool alcohols B. P.; (-)-Cholesterol; Tegolan (VAN); Cholest-5-en-3-beta-ol; 5:6-Cholesten-3beta-ol; Tegolan; 3beta-Hydroxycholest-5-ene; 5-Cholesten-3beta-ol; Cholest-5-en-3-ol (3beta)-; 3-beta-Hydroxycholest-5-ene; (3beta)-cholest-5-en-3-ol; CCRIS 2834; Dastar; HSDB 7
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5997
ChEBI ID
CHEBI:16113
CAS Number
CAS 57-88-5
TTD Drug ID
DMR3J6S
VARIDT Drug ID
DR00036

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
Drug Status:
Clinical Trial Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CT-2584 DMU2ZFK Solid tumour/cancer 2A00-2F9Z Phase 3 [11]
Sphingosine DMO1FTI N. A. N. A. Phase 1 [12]
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [13]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [14]
Methotrexate DM2TEOL Anterior urethra cancer Approved [15]
Folic Acid DMEMBJC Colorectal carcinoma Approved [16]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [15]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [15]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [17]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [15]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [18]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [19]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [20]
Methotrexate DM2TEOL Anterior urethra cancer Approved [21]
Folic Acid DMEMBJC Colorectal carcinoma Approved [22]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [23]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [24]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [9]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [25]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [9]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [26]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [27]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
FENOFIBRIC ACID DMGO2MC Cardiovascular disease BA00-BE2Z Approved [28]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cholinephosphate cytidylyltransferase (PCYT1B) TTUAIKM PCY1B_HUMAN Activator [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
ATP-binding cassette sub-family A member 12 (ABCA12) DT7LDG0 ABCAC_HUMAN Substrate [3]
Niemann-Pick C1-like protein 1 (SLC65A2) DT1UMXN NPCL1_HUMAN Substrate [4]
ATP-binding cassette sub-family G member 1 (ABCG1) DTLYEPH ABCG1_HUMAN Substrate [5]
ATP-binding cassette sub-family A member 5 (ABCA5) DT195NK ABCA5_HUMAN Substrate [6]
ATP-binding cassette sub-family A member 2 (ABCA2) DTJ4NEG ABCA2_HUMAN Substrate [7]
ATP-binding cassette sub-family A member 1 (ABCA1) DT61TWI ABCA1_HUMAN Substrate [8]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [9]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2718).
2 Regulation of CTP: phosphocholine cytidylyltransferase activity by the physical properties of lipid membranes: an important role for stored curvature strain energy. Biochemistry. 2001 Sep 4;40(35):10522-31.
3 ABCA12 regulates ABCA1-dependent cholesterol efflux from macrophages and the development of atherosclerosis. Cell Metab. 2013 Aug 6;18(2):225-38.
4 Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004 Feb 20;303(5661):1201-4.
5 Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):139-43.
6 Mutations in the cholesterol transporter gene ABCA5 are associated with excessive hair overgrowth. PLoS Genet. 2014 May 15;10(5):e1004333.
7 The ATP-binding cassette transporter-2 (ABCA2) regulates cholesterol homeostasis and low-density lipoprotein receptor metabolism in N2a neuroblastoma cells. Biochim Biophys Acta. 2011 Dec;1811(12):1152-64.
8 ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions. J Lipid Res. 2003 Jul;44(7):1373-80.
9 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
10 Cholesterol interaction with the daunorubicin binding site of P-glycoprotein. Biochem Biophys Res Commun. 2000 Oct 5;276(3):909-16.
11 Pharmacological inhibition of phosphatidylcholine biosynthesis is associated with induction of phosphatidylinositol accumulation and cytolysis of neoplastic cell lines. Cancer Res. 2000 Sep 15;60(18):5204-13.
12 Sphingosine inhibits the activity of rat liver CTP:phosphocholine cytidylyltransferase. J Biol Chem. 1990 Jul 15;265(20):11746-50.
13 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
14 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
15 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
16 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
17 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
18 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
19 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
20 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
21 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
22 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
23 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
24 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
25 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
26 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
27 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
28 Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1193-7.